IASLC: Ivonescimab vs Pembrolizumab as First-Line Treatment in …
WEBIvonescimab is a bispecific antibody targeting both PD-1 and the vascular endothelial growth factor (VEGF). It showed activity as front-line therapy in the phase II AK112-202 study. 2 The phase III HARMONi-2 trial randomly assigned 398 patients from 55 centers in China to receive either ivonescimab (20 mg/kg) or pembrolizumab (200 mg) every 3 ...
Ivonescimab Outperforms Pembrolizumab as Frontline Therapy in …
WEBSep 8, 2024 · Ivonescimab produced a significant improvement in PFS vs pembrolizumab as frontline therapy in patients with PD-L1–positive advanced NSCLC.
Ivonescimab outperforms pembrolizumab in study for first-line …
WEBSep 8, 2024 · Data from a Phase 3 study has revealed that ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free survival compared to pembrolizumab for...
Akeso's Ivonescimab Head-to-Head Phase III Data Against …
WEBSep 8, 2024 · Ivonescimab as first-line treatment for PD-L1 positive NSCLC significantly extends median progression-free survival (mPFS) compared to pembrolizumab, with both statistical and clinical...
Promising Anti-Tumor Activity and Safety of Ivonescimab in …
WEB5 days ago · The presentation was entitled, The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC), presenting the current ...
Ivonescimab Monotherapy Decisively Beats Pembrolizumab …
WEBMay 30, 2024 · Ivonescimab, known as AK112 is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis...
Phase II results of ivonescimab (AK112/ SMT112), a novel PD …
WEBMay 31, 2023 · Ivonescimab is a novel anti-PD-1/VEGF bispecific antibody. The bispecific approach to these targets has the potential to recalibrate the malignant immuno-architecture in favor of a more immune-responsive and anti-tumor microenvironment.
Ivonescimab combined with chemotherapy in patients with EGFR …
WEBMay 29, 2024 · Background: Ivonescimab (AK112/SMT112) is a anti-PD-1/VEGF bispecific antibody. Previous phase I/II clinical studies have shown potential efficacy of ivonescimab in NSCLC patients with EGFR mutations who had failed prior EGFR-TKIs therapies.
Keytruda beaten by Summit’s bispecific in NSCLC - Yahoo Finance
WEB22 hours ago · SMMT. On 8 September 2024, Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific monoclonal antibody that binds to vascular ...
Two Ivonescimab (PD-1/VEGF) Results including Phase 3 …
WEBAug 11, 2024 · Ivonescimab was granted marketing approval for the treatment of epidermal growth factor receptor ("EGFR") mutated locally advanced or metastatic non-squamous non-small cell lung cancer...